AYTU
Aytu BioPharma Inc (AYTU)
Healthcare • NASDAQ • $2.05+3.54%
- Symbol
- AYTU
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $2.05
- Daily Change
- +3.54%
- Market Cap
- $22.17M
- Trailing P/E
- N/A
- Forward P/E
- 13.16
- 52W High
- $3.07
- 52W Low
- $1.80
- Analyst Target
- $9.67
- Dividend Yield
- 0.00%
- Beta
- 0.18
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions f…
Company websiteResearch AYTU on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.